Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

New cannabinoid CB1 receptor antagonists presented by sanofi-aventis

Jan. 13, 2011

Anticocaine vaccine dAd5GNC shows promise in mice

Jan. 11, 2011

Lundbeck completes two phase III trials of nalmefene for alcohol dependence

Jan. 3, 2011

Preliminary phase Ib/IIa data presented on ibudilast in opioid addiction

Dec. 15, 2010

Orexo's new sublingual tablet formulation of buprenorphine/naloxone completes phase I trial

Dec. 15, 2010

Aoxing Pharma begins trial of sublingual buprenorphine/naloxone for opioid addiction

Dec. 13, 2010

Alkermes presents phase II data on ALKS-33 in alcohol dependence

Dec. 10, 2010

CBLB-502 receives FDA orphan drug status for prevention of death following irradiation

Dec. 1, 2010

Enrollment completed in Nabi Biopharma' second phase III NicVAX trial

Nov. 10, 2010

Nicotine vaccine NIC-002 enters phase II study

Nov. 8, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...